Phase 4 trial in 204 adults with rifampicin-resistant TB in South Africa: a 6-month WGS-guided, AI-selected regimen vs standard care gave similar bacteriological response (primary; p=0.26) and fewer unfavourable outcomes in mITT (24% vs 42%), mostly less loss to follow-up.
RCTn = 204
Van Rie et al. Whole genome sequencing precision medicine strategy to shorten treatment for rifampicin-resistant tuberculosis (SMARTT): a pragmatic, randomised, single-blind phase 4 trial